ACXP (Acurx Pharmaceuticals, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ACXP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-22 | James J. Donohue | Director | A | — | — |
| 2026-04-22 | JACK H DEAN | Director | A | — | — |
| 2026-04-22 | Carl Sailer | Director | A | — | — |
| 2026-04-22 | ROBERT J DELUCCIA | Director | A | — | — |
| 2026-04-22 | THOMAS L HARRISON | Director | A | — | — |
| 2026-04-22 | DAVID P LUCI | President and CEO | A | — | — |
| 2026-04-22 | Robert G. Shawah | Chief Financial Officer | A | — | — |
| 2026-04-22 | Joseph C Scodari | Director | A | — | — |
| 2025-02-06 | ROBERT J DELUCCIA | Director | A | — | — |
| 2025-02-06 | Robert G. Shawah | Chief Financial Officer | A | — | — |
| 2025-02-06 | DAVID P LUCI | President and CEO | A | — | — |
| 2025-01-08 | Carl Sailer | Director | Buy | — | — |
| 2025-01-08 | Joseph C Scodari | Director | Buy | — | — |
| 2025-01-08 | DAVID P LUCI | President and CEO | Buy | — | — |
| 2025-01-08 | JACK H DEAN | Director | Buy | — | — |
| 2025-01-08 | James J. Donohue | Director | Buy | — | — |
| 2025-01-08 | ROBERT J DELUCCIA | Director | Buy | — | — |
| 2024-06-18 | Carl Sailer | Director | A | — | — |
| 2024-06-18 | THOMAS L HARRISON | Director | A | — | — |
| 2024-06-18 | James J. Donohue | Director | A | — | — |
| 2024-06-18 | Joseph C Scodari | Director | A | — | — |
| 2024-06-18 | JACK H DEAN | Director | A | — | — |
| 2024-04-03 | DAVID P LUCI | President and CEO | A | — | — |
| 2024-04-03 | ROBERT J DELUCCIA | Director | A | — | — |
| 2024-04-03 | Robert G. Shawah | Chief Financial Officer | A | — | — |
| 2024-01-22 | Carl Sailer | Director | M | — | — |
| 2024-01-04 | ROBERT J DELUCCIA | Director | MIXED | — | — |
| 2024-01-04 | DAVID P LUCI | President and CEO | M | — | — |
| 2023-06-16 | James J. Donohue | Director | A | — | — |
| 2023-06-16 | JACK H DEAN | Director | A | — | — |
| 2023-06-16 | Carl Sailer | Director | A | — | — |
| 2023-06-16 | Joseph C Scodari | Director | A | — | — |
| 2023-06-16 | THOMAS L HARRISON | Director | A | — | — |
| 2023-02-24 | DAVID P LUCI | President and CEO | A | — | — |
| 2023-02-24 | ROBERT J DELUCCIA | Director | A | — | — |
| 2023-02-24 | Robert G. Shawah | Chief Financial Officer | A | — | — |
| 2022-07-29 | ROBERT J DELUCCIA | Director | Buy | — | — |
| 2022-07-29 | Carl Sailer | Director | Buy | — | — |
| 2022-07-29 | DAVID P LUCI | President and CEO | Buy | — | — |
| 2021-11-24 | Carl Sailer | Director | Buy | — | — |
| 2021-11-22 | DAVID P LUCI | President and CEO | Buy | — | — |
| 2021-11-22 | ROBERT J DELUCCIA | Director | Buy | — | — |
| 2021-09-10 | Carl Sailer | Director | Buy | — | — |
| 2021-07-06 | JACK H DEAN | Director | A | — | — |
| 2021-07-06 | THOMAS L HARRISON | Director | A | — | — |
| 2021-07-06 | Robert G. Shawah | Chief Financial Officer | A | — | — |
| 2021-07-06 | DAVID P LUCI | President and CEO | A | — | — |
| 2021-07-06 | Joseph C Scodari | Director | A | — | — |
| 2021-07-06 | ROBERT J DELUCCIA | Director | A | — | — |
| 2021-07-06 | Carl Sailer | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 55,627 | — |
| — | Director | 50,702 | — |
| — | Director | 7,109 | — |
| — | Director | 1,385 | — |
| — | Director | 1,377 | — |
| — | Director | 1,118 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ACXP quote page; the site-wide leaderboard is on the insider transactions hub.